ARQT250321C00017500 Option on Arcutis Biotherapeutics

An 'Out of The Money' option on Arcutis has a strike price that Arcutis Stock has yet to reach, meaning the option has no intrinsic value. 'Out of The Money' options are usually less costly than 'In The Money' options, making them more desirable to traders with smaller amounts of capital. Some of the uses for Arcutis Biotherapeutics' 'Out of The Money' options include buying the options if you expect a big move in Arcutis Biotherapeutics' stock. Since 'Out of The Money' options have a lower up-front cost (i.e., no intrinsic value) than 'In The Money' options, buying it is a reasonable choice.

Arcutis Biotherapeutics' Option Greeks for the contract ending on 2025-03-21 at a strike price of 17.5 measures the various factors that affect its cost and calculated using a theoretical options pricing model. It helps investors make more informed decisions about whether to trade this option contract or when to trade it. In addition to Arcutis Biotherapeutics' option greeks, its implied volatility helps estimate the risk of Arcutis Biotherapeutics stock implied by the prices of the options on Arcutis Biotherapeutics' stock.

Put options written on Arcutis Biotherapeutics grant holders of the option the right to sell a specified amount of Arcutis Biotherapeutics at a specified price within a specified time frame. The put buyer has a limited loss and, while not fully unlimited gains, as the price of Arcutis Stock cannot fall below zero, the put buyer does gain as the price drops. So, purchasing a put option on Arcutis Biotherapeutics is like buying insurance aginst Arcutis Biotherapeutics' downside shift.

By selling Arcutis Biotherapeutics' put option, the investors signal their bearish sentiment. A short position in a put option written on Arcutis Biotherapeutics will generally make money when the underlying price is above the strike price. Therefore Arcutis Biotherapeutics' put payoff at expiration depends on where the Arcutis Stock price is relative to the put option strike price. The breakeven price of 17.94 is the critical point that divides the payoff function into two parts. Below the breakeven price, the payoff is dropping and negative (the seller makes a loss). Above the breakeven price, the payoff line is upward sloping as the option payoff increases in proportion to Arcutis Biotherapeutics' price. Finally, at the strike price of 17.5, the payoff chart is constant and positive.

Arcutis Biotherapeutics' option chain is a display of a range of information that helps investors for ways to trade options on Arcutis. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Arcutis. It also shows strike prices and maturity days for a Arcutis Biotherapeutics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone.

When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.